Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05913089
Other study ID # TQB2450-II/III-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 14, 2023
Est. completion date December 2026

Study information

Verified date December 2022
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Shugeng Gao, Doctor
Phone +86 13901362568
Email 13901362568@139.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer. The part I study was planned to enroll 58 subjects, 1:1 randomized into two cohorts. The treatment regimen was as follows: Cohort 1: 3-4 cycles of TQB2450 combined with chemotherapy, surgery should be performed 4-6 weeks after the last administration, and TQB2450 therapy should be continued for 1 year after surgery. Cohort 2: 4 cycles of TQB2450 combined with 3 cycles of anlotinib hydrochloride capsule. Surgery was performed 4-6 weeks after the last dose and continued for 1 year starting 4 weeks after surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date December 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - patients with stage II-IIIB (T3N2M0 only) Non-Small Cell Lung Carcinoma (NSCLC) and determined to be eligible for curable R0 excision, after pathologic diagnosis of puncture specimens; - =18 years old (calculated on the date of signing the informed consent); Both men and women; Eastern Cooperative Oncology Group (ECOG) score 0~1; Predicted survival =3 months; - Have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria within 28 days prior to initiation of treatment; - Has not received systemic antitumor therapy, including radiotherapy, chemotherapy and immunotherapy; - Agree to provide fresh or 6 month tumor tissue for programmed death ligand -1 (PD-L1) testing. - Major organs are functioning well. - Women of reproductive age should agree that they must use effective birth control during the study period and for 6 months after the study, and that a negative serum or urine pregnancy test occurred within 7 days prior to study enrollment; Men should agree that effective contraception must be used during the study period and for 6 months after the study period ends. - The subjects voluntarily joined the study and signed the informed consent with good compliance. Exclusion Criteria: - Present or complication with other malignancies within 5 years. - Subjects are known to have genetic abnormalities with approved targeted drug therapy. - Cirrhosis, active hepatitis; - Cardio-cerebrovascular abnormalities; - Subjects with severe active infection within 4 weeks prior to initiation of study treatment; Or unexplained fever >38.0 ? occurred during screening and before first administration; - Patients with active tuberculosis within 1 year prior to enrollment; - Immunodeficiency disease; - History of active autoimmune disease or autoimmune disease; - Preparing for or having previously received an organ transplant, or having received a hematopoietic stem cell transplant within 60 days prior to initial medication, or having a significant host transplant response; - Patients who required immunosuppressive, systemic, or absorbable topical hormone therapy for immunosuppressive purposes and continued use within two weeks prior to randomization - Severe infection of grade 4 or higher occurred within 1 year prior to initiation of study therapy; - Severe lung disease; - History of pituitary or adrenal dysfunction; - History of severe mental disorder; - History of drug abuse, alcoholism or drug use; - Participated in clinical trials of other drugs within 30 days; - History of live attenuated vaccine vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period; - Received Chinese patent drugs with anti-tumor indications specified in the National Medical Product Administration approved drug package inserts within 2 weeks prior to initiation of administration - Had major surgery within 4 weeks prior to initiation of medication; - Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the investigator's opinion, may increase the risks associated with study participation or may interfere with the interpretation of the study results, or are otherwise unsuitable for participation in the clinical study; - The compliance of patients to participate in this clinical study is estimated to be insufficient.

Study Design


Intervention

Drug:
TQB2450 injection + Chemotherapy
TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1). Chemotherapy is a systematic treatment that kill fast growing cells.
TQB2450 injection + Anlotinib Hydrochloride Capsule
TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1). Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China Beijing Chaoyang Hospital, Capital Medical University Beijing Beijing
China Beijing Chest Hospital, Capital Medical University Beijing Beijing
China Cancer Hospital of Chinese Academy of Medical Sciences Beijing Beijing
China Fujian Medical University Union Hospital Fuzhou Fujian
China Shanghai Chest Hospital Shanghai Shanghai
China Shanxi Cancer Hospital Taiyuan Shanxi
China Tianjin Chest Hospital Tianjin Tianjin
China Tianjin Medical University General Hospital Tianjin Tianjin
China Weifang People's Hospital Weifang Shandong

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major pathologic response (MPR) MPR defined as the percentage of subjects with a residual surviving tumor less than or equal to 10% after surgery. Baseline up to 60 months.
Secondary Overall survival (OS) From randomization to the time of death from any cause. Baseline up to 60 months.
Secondary 2/3 year OS rate The ratio of two-year survival to three-year survival. Baseline up to 36 months.
Secondary Event free survival (EFS) assessed by the investigator. From the time of randomization to the occurrence of a predetermined event, including death, disease progression, change to chemotherapy, change to chemotherapy, addition of other treatments, occurrence of fatal or intolerable side effects, etc. Baseline up to 60 months.
Secondary Disease free survival (DFS) assessed by Blinded Independent Central Review (BICR) The time from randomization to the onset of tumor recurrence or death from any cause. Baseline up to 60 months.
Secondary Pathological complete response (pCR) Ratio of patients with no residual cancer cells found in the pathological examination after treatment. Baseline up to 4 months.
Secondary R0 resection rate The proportion of subjects who could undergo R0 resection, which is one of the surgery-related end points. Baseline up to 4 months.
Secondary Surgical delay rate The proportion of subjects who could not undergo surgery in time after neoadjuvant therapy. Baseline up to 4 months.
Secondary Pathological downgrading rate The proportion of patients with reduced lung cancer stage determined by pathological results after surgery. Baseline up to 4 months.
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1